Skip to main content

Olon in enzymatic expansion

In partnership with Aguettant Pharmarmaceutical, Italy’s Olon Group is to expand and renovate its plant in Mulazzano, which is dedicated to the production by enzymatic transformation. It will install reactors, filters and ancillary equipment, as well as automating and digitalising some steps performed there.

Seqens takeover confirmed

SK Capital Partners has announced that it, Eurazeo and other shareholders in Seqens have entered a formal agreement for it to acquire Seqens. This follows a period of exclusive negotiations and the agreement of the employee representative body. This remains subject to regulatory approval. S

Minafin reorganises itself

As “part of its strategy to meet the evolution of customer needs in fine chemicals and services”, the Minafin Group has reorganised itself into three divisions, each with its own CEO, with effect from 1 October. They are:

* Health Chemistry, comprising the pharmaceutical activities of Minakem CDMO, Minakem Generics and HPAPIs, led by a CEO who is as yet unannounced

* Green Chemistry, comprising the mainly non-pharma activities of Pennakem, Minasolve, Minagro and EcoXtract, under Gust Desmedt

Further buy for Aceto

Aceto has acquired A&C Bio Buffer, a GMP manufacturer of custom buffer and chemical blends for the manufacture of biopharmaceutical drug products. This follows the acquisition earlier this year of A&C, a US manufacturer of GMP speciality excipients and custom process systems that had owned the Irish facility until then.

Vertellus to buy Chemtrade businesses

Vertellus has signed a definitive agreement to acquire the potassium chloride, caustic pellets and vaccine adjuvant businesses of diversified US chemical firm Chemtrade. Terms were not disclosed. The transaction is expected to close during Q4, subject to regulatory approval and customary closing conditions.

PharmaZell and Novasep to merge

PharmaZell, a German-based producer of speciality APIs, and France’s CDMO Groupe Novasep are to merge under the ownership of PharmaZell’s current majority shareholder, private equity firm Bridgepoint. This remains subject to consultation with employees and other closing conditions.

New owner for Envigo

Inotiv, a US CRO specialising in nonclinical and analytical drug discovery and development services, has reached an agreement to acquire research models and services Envigo. The cash and shares deal gives UK-headquartered Envigo an enterprise value of about $545 million, and the combined company one of around $1.2 billion.

Subscribe to Pharmaceuticals